Trump’s Impact on Drug Pricing and Republican Strategy
President Trump has made significant strides in drug pricing, and a recent national survey of likely voters suggests that these achievements could be a crucial advantage for Republicans as they head into the 2026 midterms.
The survey, conducted from March 10 to March 14, 2026, included 2,000 likely voters and has a margin of error of ±2.2% at a 95% confidence level. It highlights the depth of concerns voters have regarding healthcare costs and the substantial political opportunity for Republicans willing to address these issues head-on.
The primary concern for voters is the cost of health insurance. A notable 51% of likely voters rank it as their top healthcare issue. Other concerns, such as hospital bills and drug prices, lag significantly behind. This issue is especially critical for those with private insurance—76% cite insurance costs as their main worry—and for seniors, where the figure is 71%. These voters aren’t just looking for understanding; they’re calling for action.
What happens if a Republican candidate endorses Trump’s proposal to end taxpayer subsidies to large insurance companies and instead redirect that money to individuals so they can select their preferred health insurance plan? Our poll indicates that voters are 61% more likely to support such a candidate. Interestingly, even more than 40% of Democrats are inclined to vote for a Republican who backs this approach.
Left-leaning media and Democratic critics have spent considerable time arguing that Trump’s voluntary Most Favored Nation (MFN) pricing agreements, often referred to as TrumpRx, are inadequate. However, our data counters this narrative. Nearly 73% of likely voters support these pricing agreements, with only 13% opposed. Furthermore, by a margin of nearly two-to-one (55% to 29%), voters feel that voluntary negotiations yield better results than government-mandated pricing through laws or executive orders.
Support for these voluntary drug price agreements also seems to bolster Republican candidates. Almost 60% of independent voters indicate they would be more likely to vote for candidates who favor these policies.
Additionally, Trump’s message regarding other countries’ obligations resonates well. Seventy-two percent of voters believe it’s time for other nations to cover their fair share for prescription drug costs, with nearly unanimous agreement among Republicans (92%) and a strong majority of Independents (65%) and Democrats (56%). Voters recognize that they’ve been subsidizing low drug prices worldwide for years, and they want it to change.
Once again, Republican candidates can gain favor by supporting legislation aimed at tackling this issue of foreign freeloading, making voters 60% more likely to back them.
There are numerous other paths for Republicans to gain traction in the upcoming midterm elections: advocating for insurance companies to pass on manufacturer discounts to patients (67% more likely), supporting the option for every American to benefit from Health Savings Accounts (59% more likely), and enabling Medicare seniors to utilize manufacturer co-pay cards (65% more likely).
President Trump has shifted the dialogue around drug pricing, successfully bringing pharmaceutical companies to the negotiation table and securing immediate savings for American patients. Now, it’s up to Congressional Republicans to act on this momentum. If they wish to maintain their majorities in November, they must not let Democrats claim the healthcare affordability narrative by default. Trump has laid out a strategy, and the voters indicate it resonates. The essential question remains: will Congress take action?
